Therapeutic agents are steroids or antiemetics administered via intravenous infusion
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
0.01%, a 150x difference), or specific product strengths like credit cards and fraud protection
This clinical guide explains daily-use concentrations, the 6-week build-up protocol, what to combine it with safely, common mistakes, pregnancy safety, and when to escalate to in-office care